NCT07458269: Efficacy and Safety of Ribupatide (KAI-9531) Administered Once Weekly in Participants Living With Obesity Who Do Not Have Diabetes
- State
- Under way
- Phase
- Phase 2
- People
- 264 taking part
- Started
- 4 Mar 2026
- Primary completion
- May 2027
- Arms
- Ribupatide: Dose 1, Ribupatide: Dose 2, Ribupatide: Dose 3, Ribupatide: Dose 4
- Results
- None posted
- 4 Mar 2026: Trial started
- 9 Mar 2026: Trial registered